Reuters logo
BRIEF-Lonza Group and TiGenix sign agreement for manufacture treatment of complex perianal fistulas in Crohn's disease
February 12, 2015 / 6:22 AM / 3 years ago

BRIEF-Lonza Group and TiGenix sign agreement for manufacture treatment of complex perianal fistulas in Crohn's disease

Feb 12 (Reuters) - Lonza Group AG :

* Says TiGenix and Lonza sign agreement for manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s disease

* Says to manufacture CX601 product for TiGenix’s phase 3 trial in U.S. at Lonza’s Walkersville, Maryland (US) facility Source text for Eikon: Further company coverage:, (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below